Overall Survival and Progression-Free Survival With Endocrine Therapy for Hormone Receptor-Positive, HER2-negative Advanced Breast Cancer: Review

Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758834017728928
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde
GynecologyMidwiferyMaternityObstetrics
2019English

Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2−negative Endocrine-Refractory Metastatic Breast Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2016English

Prm155 - Joint Modeling of Overall Survival and Progression Free Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Association of MDM2 Expression With Shorter Progression-Free Survival and Overall Survival in Patients With Advanced Pancreatic Cancer Treated With Gemcitabine-Based Chemotherapy

PLoS ONE
Multidisciplinary
2017English

BCT Score Predicts Chemotherapy Benefit in Asian Patients With Hormone Receptor-Positive, HER2-negative, Lymph Node-Negative Breast Cancer

PLoS ONE
Multidisciplinary
2018English

Multivariate Network Meta-Analysis of Progression Free Survival and Overall Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Therapeutic Effect of Apatinib on Overall Survival Is Mediated by Prolonged Progression-Free Survival in Advanced Gastric Cancer Patients

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy